Moderna
Moderna, Inc. (NASDAQ: MRNA) is a pioneer and leader in mRNA medicine, operating through a diversified pipeline spanning infectious disease vaccines, oncology therapeutics, and rare disease therapeutics. The company's mission centers on delivering the greatest possible impact to people through mRNA medicines by… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Moderna does
In the company’s own words
Moderna, Inc. (NASDAQ: MRNA) is a pioneer and leader in mRNA medicine, operating through a diversified pipeline spanning infectious disease vaccines, oncology therapeutics, and rare disease therapeutics. The company's mission centers on delivering the greatest possible impact to people through mRNA medicines by reimagining how medicines are made to transform disease treatment and prevention.
The company currently markets three commercial products: Spikevax and mNEXSPIKE, its COVID-19 vaccines, and mRESVIA, its respiratory syncytial virus vaccine for older adults and high-risk individuals. In 2025, Moderna achieved total revenue of $1.9 billion, primarily from COVID vaccine sales. mNEXSPIKE, launched commercially in the third quarter of 2025, has become the leading product in the U.S. retail channel.
Moderna's platform technology integrates three key components: mRNA science advancements, delivery mechanisms utilizing lipid nanoparticles, and proprietary manufacturing processes. The company views mRNA as the "software of life," enabling cells to produce specific therapeutic proteins or vaccine antigens. This approach offers inherent advantages including broad applicability across diseases, mimicry of human biology, simple chemical structure enabling rapid design modifications, and classic pharmacologic features with adjustable dosing.
Beyond commercial products, Moderna maintains a robust development pipeline of 35 therapeutic and vaccine programs, with six in late-stage development. Notable programs include intismeran autogene, an individualized neoantigen therapy in collaboration with Merck showing sustained improvement in recurrence-free survival for melanoma patients, and multiple infectious disease candidates including seasonal flu and norovirus vaccines. In rare disease, the company is advancing propionic acidemia and methylmalonic acidemia therapeutics, recently establishing a strategic collaboration with Recordati for mRNA-3927 development and commercialization.
The company operates a global manufacturing network established since 2022, including purpose-built facilities in the United States, United Kingdom, Canada, and Australia. Moderna's Marlborough, Massachusetts facility was specifically designed for intismeran production and began clinical batch supply in September 2025. The company maintains a global team focused on advancing mRNA technology across multiple disease areas and geographic markets. More information is available at www.modernatx.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- CAMBRIDGE, MA
- Fiscal year end
- December
- CIK
- 1682852
- SIC
- 2836
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Moderna — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Moderna’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Moderna and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Moderna's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Moderna's last four quarterly filings that the numbers alone won't show?”